Ceftazidime-Avibactam Combination Therapy versus Monotherapy for the Treatment Carbapenem-Resistant Gram-Negative Bacterial Infections: A Retrospective Observational Study
DOI: https://doi.org/10.2147/idr.s452805
2024-03-30
Infection and Drug Resistance
Abstract:Keyang Li, 1, &ast Debao Li, 2, &ast Hongliang Dong, 1 Dongmei Ren, 2 Dandan Gong, 1 Shubo Wang, 1 Yang Li, 1 Yuanyuan Wu, 1 Jikang Yang, 3 Wenjuan Yan, 4 Yi Li 4 1 Department of Clinical Pharmacy, Jiaozuo People's Hospital, Jiaozuo, Henan, People's Republic of China; 2 Department of Clinical Laboratory, Jiaozuo People's Hospital, Jiaozuo, Henan, People's Republic of China; 3 Infectious Diseases Department, Jiaozuo People's Hospital, Jiaozuo, Henan, People's Republic of China; 4 Department of Clinical Laboratory, Henan Provincial People's Hospital, Zhengzhou, Henan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Wenjuan Yan; Yi Li, Department of Clinical Laboratory, Henan Provincial People's Hospital, Weiwu Road 7&num, Jinshui District, Zhengzhou, Henan, 450003, People's Republic of China, Tel +86 15225061830 ; +86 15939039006, Email ; Purpose: Since the introduction of ceftazidime–avibactam (CZA) in the Chinese market, accumulating clinical evidence has substantiated its efficacy in the treatment of infections caused by carbapenem-resistant gram-negative bacteria (CR-GNB). Nevertheless, an ongoing debate persists concerning the choice between monotherapy and combination therapy when devising clinical anti-infection protocols. Patients and Methods: This retrospective, single-center observational study enrolled patients with CR-GNB infections who received CZA treatment between December 2019 and August 2023. The primary outcome assessed was 30-day mortality, and the secondary outcome measured was 14-day bacterial clearance. A multivariate Cox regression model was used to identify variables that were independently associated with 30-day mortality rate. Results: Eighty-three patients were enrolled in the study; of which, 45 received CZA monotherapy, whereas 38 received combination therapy. The overall 30-day mortality rate was 31.3%, and no significant difference was observed in the 30-day mortality rates between the CZA combination therapy and monotherapy groups (31.6% vs 31.1%, p=0.963). After adjustment by propensity score matching, the 30-day mortality rate was not significantly different between the two groups (28.6% vs 31.4%, p=0.794). Multivariate COX analysis revealed that age and SOFA score were independent predictors of 30-day mortality. Conclusion: Combination therapy with CZA and other antimicrobials was not found to have an advantage over monotherapy in reducing the 30-day mortality rate. Keywords: ceftazidime-avibactam, carbapenem-resistant gram-negative bacteria, combination therapy K. pneumoniae carbapenemase Multidrug-resistant gram-negative bacterial infections have persistently been among the most urgent challenges in the field of infectious diseases. 1 Owing to limited antibiotic options and high mortality rates, infections caused by multidrug- and extensively drug-resistant gram-negative bacteria have become a major challenge for global health organizations. 2,3 For decades, carbapenems have been the preferred choice for treating infections caused by these pathogens. 4–7 However, the emergence and spread of carbapenemases threatens their efficacy as the last line of defense against multidrug-resistant bacteria. 8,9 For domestic use, the most prevalent carbapenemases are Klebsiella pneumoniae carbapenemases (KPC), 10 which belong to the Ambler class A enzymes and can hydrolyze all available traditional β-lactam antibiotics. Ceftazidime-avibactam (CZA) is a novel combination of the cephalosporin antibiotic ceftazidime and non-β-lactam β-lactamase inhibitor avibactam. CZA exhibits broad activity against Ambler class A, C, and certain class D enzymes. 11 It has been approved for treating complicated urinary tract and complicated intra-abdominal infections, including hospital-acquired and ventilator-associated pneumonia, as well as for gram-negative bacterial infections in adult patients with limited treatment options. 12,13 Although there have been published reports of the clinical use of CZA in practical settings. 14–19 The Infectious Diseases Society of America (IDSA) expert consensus released in 2023 recommends monotherapy for treating gram-negative bacteria that do not produce metalloenzymes, 20 controversy exists regarding whether CZA should be used as a monotherapy or in combination with other antimicrobial agents in patients with carbapenem-resistant gram-negative bacterial (CR-GNB) infections in China. 21 Therefore, we conducted a single-center re -Abstract Truncated-
pharmacology & pharmacy,infectious diseases